Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Losartan Potassium prices in Germany, the highest-cost reporting region, rose 7.1% in H1 2026, climbing from USD 50.8/KG in Q1 to USD 54.4/KG by Q2 as recovering antihypertensive, heart failure, and diabetic nephropathy treatment formulation procurement and firmer tetrazole synthesis intermediate costs reversed the H2 2025 API market softening. Globally, the average rose from USD 35.95/KG in Q1 to USD 38.47/KG in Q2, a 7.0% gain. For H2 2026, a global average of USD 38.70-42.80/KG is expected, with continued firming on Middle East supply disruptions and growing antihypertensive and cardiovascular protection sector demand globally.
Losartan Potassium is the potassium salt of losartan, the first orally active angiotensin II AT1 receptor antagonist of the sartan antihypertensive class, produced by multi-step synthesis from imidazole acetic acid and 4-bromomethylbiphenyl-2-carbonitrile precursors through N-alkylation, tetrazole ring formation from the nitrile intermediate using sodium azide cycloaddition, n-butyl side chain introduction, and potassium salt formation. The compound selectively and reversibly blocks the AT1 receptor, preventing angiotensin II-mediated vasoconstriction, aldosterone release, renal sodium reabsorption, and sympathetic activation. An active carboxylic acid metabolite EXP3174 provides the majority of AT1 blocking activity and a longer pharmacodynamic duration than the parent compound. The largest pull comes from first-line antihypertensive prescribing, where losartan’s effective blood pressure control, absence of ACE inhibitor cough, and established tolerability support broad adoption. Heart failure hospitalisation and mortality reduction, and diabetic nephropathy progression reduction with proteinuria lowering in hypertensive type 2 diabetic patients add significant demand. Tetrazole and imidazole synthesis intermediate costs, antihypertensive and diabetic nephropathy treatment prescription volumes, and regional API production capacity all feed into the price.
The balance of supply and demand for Losartan Potassium through H2 2026 leans moderately firm. Tetrazole and imidazole synthesis intermediate costs firmed from Middle East chemical supply disruptions. Antihypertensive prescribing volumes and heart failure and diabetic nephropathy management demand are growing with ageing demographics and hypertension treatment access expansion.
The main upside risk is synthesis intermediate cost increases alongside accelerating antihypertensive access programme scale-up. The main downside risk is continued Chinese and Indian API surplus and generic competition maintaining competitive price pressure below forecast.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 38.70 - 42.80 | Synthesis cost firming and antihypertensive/nephropathy demand |
| United States | 41.60 - 45.70 | Steady antihypertensive and diabetic nephropathy demand holds firm |
| China | 27.40 - 31.50 | Large API capacity keeps it the most affordable |
| Germany | 55.10 - 59.20 | High synthesis and energy costs keep it the most expensive |
| India | 39.80 - 43.90 | Growing antihypertensive and export demand holds a firm middle |
US Losartan Potassium prices averaged USD 44.1/KG in Q2 2026, up 7.0% from USD 41.2/KG in Q1 2026. Firmer synthesis intermediate costs and recovering antihypertensive and diabetic nephropathy procurement drove consistent buying through the quarter.
Why did the price of Losartan Potassium change in Q2 2026 in the United States?
Firmer tetrazole synthesis intermediate costs raised the API production floor. Antihypertensive, heart failure, and diabetic nephropathy formulation procurement lifted buying. Cardiovascular protection and Marfan syndrome treatment demand provided additional support near USD 44.1/KG.
Chinese Losartan Potassium prices averaged USD 30.5/KG in Q2 2026, up 7.0% from USD 28.5/KG in Q1 2026, the lowest among the tracked markets. Spring antihypertensive and heart failure export and domestic procurement lifted buying. Firmer domestic synthesis costs raised the production floor despite domestic API capacity.
Why did the price of Losartan Potassium change in Q2 2026 in China?
Spring antihypertensive and heart failure export and domestic procurement lifted buying. Firmer domestic tetrazole synthesis intermediate costs raised the production floor. Domestic API capacity kept China the most affordable source.
German Losartan Potassium prices averaged USD 54.4/KG in Q2 2026, up 7.1% from USD 50.8/KG in Q1 2026, the highest among the tracked markets. Higher synthesis intermediate and energy costs elevated European API production economics. Consistent antihypertensive, heart failure, and diabetic nephropathy demand maintained buying.
Why did the price of Losartan Potassium change in Q2 2026 in Germany?
Higher tetrazole synthesis intermediate and energy costs elevated European API production economics. Middle East supply disruptions added cost premiums to synthesis substrate chains. Consistent antihypertensive and cardiovascular formulation procurement maintained buying near USD 54.4/KG.
Indian Losartan Potassium prices averaged USD 41.8/KG in Q2 2026, up 6.9% from USD 39.1/KG in Q1 2026. Growing antihypertensive and heart failure export and domestic demand supported buying. Firmer synthesis import costs raised the production floor.
Why did the price of Losartan Potassium change in Q2 2026 in India?
Growing antihypertensive and heart failure export and domestic procurement lifted buying. Firmer tetrazole synthesis import costs raised the production floor. Diabetic nephropathy and cardiovascular export demand provided additional support near USD 41.8/KG.
US Losartan Potassium prices averaged USD 41.2/KG in Q1 2026, recovering about 4.0% from the Q4 2025 softening trough. Recovering antihypertensive and heart failure demand and firming synthesis costs held the market near USD 41.2/KG.
Why did the price of Losartan Potassium change in Q1 2026 in the United States?
Recovering antihypertensive and heart failure formulation procurement maintained buying. Firming tetrazole synthesis intermediate costs raised the production floor. The market recovered to USD 41.2/KG from the H2 2025 API softening trough.
Chinese prices averaged USD 28.5/KG in Q1 2026, recovering about 4.0% from Q4 2025. Post-Lunar New Year antihypertensive restocking and firming synthesis costs held the market near USD 28.5/KG.
Why did the price of Losartan Potassium change in Q1 2026 in China?
Post-Lunar New Year antihypertensive and heart failure restocking lifted buying. Firming domestic tetrazole synthesis costs raised the production floor. The market recovered to USD 28.5/KG from the H2 2025 trough.
German prices averaged USD 50.8/KG in Q1 2026, recovering about 4.1% from Q4 2025. Recovering antihypertensive and heart failure demand and firming synthesis and energy costs held the market near USD 50.8/KG.
Why did the price of Losartan Potassium change in Q1 2026 in Germany?
Recovering antihypertensive and heart failure procurement maintained buying. Firming synthesis intermediate and energy costs held the production floor. The market recovered to USD 50.8/KG from the H2 2025 API softening trough.
Indian prices averaged USD 39.1/KG in Q1 2026, recovering about 4.0% from Q4 2025. Growing antihypertensive and heart failure demand and firming synthesis import costs held the market near USD 39.1/KG.
Why did the price of Losartan Potassium change in Q1 2026 in India?
Growing antihypertensive and heart failure export and domestic procurement maintained buying. Firming tetrazole synthesis import costs raised the production floor. The market recovered to USD 39.1/KG from the H2 2025 trough.
Global Losartan Potassium prices declined through H2 2025 on API synthesis cost softening before recovering firmly through Q1 and Q2 2026. The average fell from USD 36.0/KG in Q2 2025 to USD 35.28/KG in Q3 and USD 34.57/KG in Q4, then recovered to USD 35.95/KG in Q1 2026 and USD 38.47/KG in Q2 2026, a net gain of about 6.9% over the window. Tetrazole and imidazole synthesis intermediate cost cycles and antihypertensive and heart failure procurement drove the H2 2025 softening and H1 2026 recovery.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 38.47 | +7.0% | ↑ Rising |
| Q1 2026 | 35.95 | +4.0% | ↑ Rising |
| Q4 2025 | 34.57 | -2.0% | ↓ Falling |
| Q3 2025 | 35.28 | -2.0% | ↓ Falling |
| Q2 2025 | 36.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Losartan Potassium prices declined through 2025 as API synthesis cost softening and competitive generic pricing weighed on the market. The global average opened near USD 36.7/KG in Q1 2025 and closed at USD 34.57/KG in Q4, a full-year decline of about 5.8%. Synthesis intermediate cost softening and Chinese API supply adequacy maintained downward pressure before the H1 2026 recovery.
US prices fell from about USD 41.5/KG in Q1 2025 to USD 39.6/KG by Q4, a decline of 4.6%. Synthesis cost softening and adequate generic API supply maintained the downward trend.
Chinese prices fell from roughly USD 28.8/KG in Q1 2025 to USD 27.4/KG by Q4, a decline of 4.9%. Domestic API capacity and competitive pricing maintained the lowest level throughout.
German prices fell from about USD 51.2/KG in Q1 2025 to USD 48.8/KG by Q4, a decline of 4.7%. Synthesis intermediate softening and moderate European antihypertensive demand maintained the trend.
Indian prices fell from roughly USD 39.5/KG in Q1 2025 to USD 37.6/KG by Q4, a decline of 4.8%. Synthesis import cost softening and competitive export pricing maintained downward pressure.
Expert Market Research: Your Source for Real-Time Losartan Potassium Price Intelligence
Expert Market Research tracks Losartan Potassium prices continuously across every major producing and consuming region. The team traces causation through tetrazole and imidazole synthesis intermediate economics, antihypertensive and cardiovascular procurement cycles, and regional API production capacity. Contact Expert Market Research today for Losartan Potassium pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
First-line antihypertensive prescribing with effective blood pressure control, absence of ACE inhibitor cough, and well-established tolerability takes the largest share. Heart failure management to reduce hospitalisation and cardiovascular mortality, and diabetic nephropathy progression reduction with proteinuria lowering in hypertensive type 2 diabetic patients also consume significant volumes globally.
The Q2 2026 average was USD 44.1/KG in the United States, USD 30.5/KG in China, USD 54.4/KG in Germany, and USD 41.8/KG in India. Germany remains the highest-priced market.
The global average rose from USD 35.95/KG in Q1 to about USD 38.47/KG in Q2, a gain of around 7.0%. Recovering antihypertensive and diabetic nephropathy demand and firmer synthesis intermediate costs drove the H1 2026 recovery from the H2 2025 softening.
Tetrazole and imidazole synthesis intermediate cost softening reduced the API production floor. Competitive generic pricing and Chinese API supply adequacy maintained downward pressure before the H1 2026 recovery.
The global average is expected in the USD 38.70 to 42.80/KG range for H2 2026, with continued firming as synthesis intermediate costs stay elevated and antihypertensive and cardiovascular protection sector demand grows globally.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on antihypertensive and cardiovascular demand, and China prices lowest on domestic API capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to tetrazole and imidazole synthesis intermediate costs, antihypertensive and heart failure prescribing volume cycles, and diabetic nephropathy management guideline adoption. Synthesis precursor prices and hypertension treatment access data are key signals.
China and India hold the largest losartan potassium API synthesis capacity. Any tetrazole synthesis intermediate cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time antihypertensive and heart failure formulation contracts around synthesis cost cycles, build cover when tetrazole signals tighten, and monitor antihypertensive prescribing volume data as the primary demand signal.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.